medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2006, Number 1

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2006; 19 (1)

Bleomycin: a lung fibrosis animal model

Cabrera BS

Language: Spanish
References: 56
Page: 53-61
PDF size: 139.43 Kb.


ABSTRACT

Bleomycin is a glycopeptide used for cancer treatment, but the therapeutic potencial of this drug is limited by its lung toxicity. The cytotoxic effect of bleomycin is dose-dependent and involves pneumonitis that proceeds to lung fibrosis (LF). Alveolar epithelial cells are the main target of bleomycin induced injury. Alveolar epithelial cell death by apoptosis is considered as a key event in the initiation and progression of LF, that is characterized by excessive deposition of extracellular matrix, mainly fibrilar collagens in the lung parenchyma. Bleomycin has been used as the main fibrogenic agent in animal models in LF basic research; in recent years, a bleomycin model developed in transgenic mice has been used to elucidate the in vivo role of a great number of biomolecules involved in LF.


REFERENCES

  1. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005;33:9-13.

  2. Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer 2005;5:102-112.

  3. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001;120:617-624.

  4. Ramotar D, Wang H. Protective mechanisms against the antitumor agent bleomycin: lessons from Saccharomyces cerevisiae. Curr Genet 2003;43:213-224.

  5. Joshi N, Grant SG. DNA double-strand break damage and repair assessed by pulsed-field gel electrophoresis. Methods Mol Biol 2005;291:121-129.

  6. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 2002;83:111-119.

  7. Kaminski N, Zuo F, Cojocaro G, et al. Use of oligonucleotide microarrays to analyze gene expression patterns in pulmonary fibrosis reveals distinct patterns of gene expression in mice and humans. Chest 2002;121(3 Suppl):31-32.

  8. Chen J, Stubbe J. Bleomycins: new methods will allow reinvestigation of old issues. Curr Opin Chem Biol 2004;8:175-181.

  9. Galm U, Hager MH, van Lanen SG, Ju J, Thorson JS, Shen B. Antitumor antibiotics: bleomycin, enediynes, and mitomycin. Chem Rev 2005;105:739-758.

  10. Bukowski MR, Zhu S, Koehntop KD, Brennessel WW, Que L Jr. Characterization of an Fe III-OOH species and its decomposition product in a bleomycin model system. J Biol Inorg Chem 2004;9:39-48.

  11. Vorobjev PE, Smith JB, Pyshnaya IA, Levina AS, Zarytova VF, Wickstrom E. Site-specific cleavage of RNA and DNA by complementary DNA-bleomycin A5 conjugates. Bioconjug Chem 2003;14:1307-1313.

  12. Abraham AT, Lin JJ, Newton DL, Rybak S, Hecht SM. RNA cleavage and inhibition of protein synthesis by bleomycin. Chem Biol 2003;10:45-52.

  13. Bukowski MR, Zhu S, Koehntop KD, Brennessel WW, Que L Jr. Characterization of an Fe III-OOH species and its decomposition product in a bleomycin model system. J Biol Inorg Chem 2004;9:39-48.

  14. Nuver J, Lutke Holzik MF, van Zweeden M, et al. Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genomics 2005; 15:399-405.

  15. O’Farrell PA, Gonzalez F, Zheng W, Johnston SA, Joshua-Tor L. Crystal structure of human bleomycin hydrolase, a self-compartmentalizing cysteine protease. Structure 1999;7:619-627.

  16. Schwartz DR, Homanics GE, Hoyt DG, Klein E, Abernethy J, Lazo JS. The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. Proc Natl Acad Sci U S A 1999;96:4680-4685.

  17. Mouse Genome Sequencing Consortium. Initial sequencing and comparative analysis of the mouse genome. Nature 2002;420:520-562.

  18. Misra RP, Duncan SA. Gene targeting in the mouse: advances in introduction of transgenes into the genome by homologous recombination. Endocrine 2002;19:229-238.

  19. Galli-Taliadoros LA, Sedgwick JD, Wood SA, Korner H. Gene knock-out technology: a methodological overview for the interested novice. J Immunol Methods 1995;181:1-15.

  20. Grande NR, Peao MN, de Sa CM, Aguas AP. Lung fibrosis induced by bleomycin: structural changes and overview of recent advances. Scanning Microscopy 1998;12:487-494.

  21. Hagimoto N, Kuwano K, Miyazaki H, et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 1997;17:272-278.

  22. Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999; 104:13-19.

  23. Aoshiba K, Yasui S, Tamaoki J, Nagai A. The Fas/Fas-ligand system is not required for bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2000;162(2 Pt 1):695-700.

  24. Wallach-Dayan SB, Izbicki G, Cohen PY, Gerstl-Golan R, Fine A, Breuer R. Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway. Am J Physiol Lung Cell Mol Physiol 200523;[E. publ. ahead of print].

  25. Borzone G, Moreno R, Urrea R, Meneses M, Oyarzun M, Lisboa C. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;163: 1648-1653.

  26. Izbicki G, Breuer R. IL-4 is not a key profibrotic cytokine in bleomycin-induced lung fibrosis model. J Immunol 2003;171:2767-2768.

  27. Gharaee-Kermani M, McGarry B, Lukacs N, Huffnagle G, Egan RW, Phan SH. The role of IL-5 in bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1998;64:657-666.

  28. Hao H, Cohen DA, Jennings CD, Bryson JS, Kaplan AM. Bleomycin-induced pulmonary fibrosis is independent of eosinophils. J Leukoc Biol 2000;68:515-521.

  29. Arras M, Louahed J, Heilier JF, et al. IL-9 protects against bleomycin-induced lung injury: involvement of prostaglandins. Am J Pathol 2005;166:107-115.

  30. Kradin RL, Sakamoto H, Jain F, Zhao LH, Hymowitz G, Preffer F. IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin. Exp Mol Pathol 2004;76:205-211.

  31. Sakamoto H, Zhao LH, Jain F, Kradin R. IL-12p40 (-/-) mice treated with intratracheal bleomycin exhibit decreased pulmonary inflammation and increased fibrosis. Exp Mol Pathol 2002;72:1-9.

  32. Nakatani-Okuda A, Ueda H, Kashiwamura S, et al. Protection against bleomycin-induced lung injury by IL-18 in mice. Am J Physiol Lung Cell Mol Physiol 2005;289:L280-L287.

  33. Frankel SK, Moats-Staats BM, Cool CD, Wynes MW, Stiles AD, Riches DW. Human insulin-like growth factor-IA expression in transgenic mice promotes adenomatous hyperplasia but not pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2005;288:L805-L812.

  34. Li J, Ortiz LA, Hoyle GW. Lung pathology in platelet-derived growth factor transgenic mice: effects of genetic background and fibrogenic agents. Exp Lung Res 2002;28:507-522.

  35. Madtes DK, Elston AL, Hackman RC, Dunn AR, Clark JG. Transforming growth factor-alpha deficiency reduces pulmonary fibrosis in transgenic mice. Am J Respir Cell Mol Biol 1999;20:924-934.

  36. Ortiz LA, Lasky J, Hamilton RF Jr, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998;24:721-743.

  37. Moore BB, Coffey MJ, Christensen P, et al. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. J Immunol 2000;165:4032-4039.

  38. Charbeneau RP, Christensen PJ, Chrisman CJ, et al. Impaired synthesis of prostaglandin E2 by lung fibroblasts and alveolar epithelial cells from GM-CSF-/- mice: implications for fibroproliferation. Am J Physiol Lung Cell Mol Physiol 2003;284:L1103-L1111.

  39. Segel MJ, Izbicki G, Cohen PY, et al. Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2003;285:L1255-L1262.

  40. Tager AM, Kradin RL, LaCamera P, et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol 2004;31:395-404.

  41. Jiang D, Liang J, Hodge J, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest 2004;114:291-299.

  42. Okuma T, Terasaki Y, Kaikita K, et al. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol 2004;204:594-604.

  43. Okazaki T, Nakao A, Nakano H, et al. Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice. J Immunol 2001;167:1977-1981.

  44. Hattori N, Degen JL, Sisson TH, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000;106:1341-1350.

  45. Sisson TH, Hattori N, Xu Y, Simon RH. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 1999;10:2315-2323.

  46. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97: 232-237.

  47. Hamaguchi Y, Nishizawa Y, Yasui M, et al. Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. Am J Pathol 2002; 161:1607-1618.

  48. Azuma A, Takahashi S, Nose M, et al. Role of E-selectin in bleomycin induced lung fibrosis in mice. Thorax 2000;55:147-152.

  49. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A 2002;99:6292-6297.

  50. Betsuyaku T, Fukuda Y, Parks WC, Shipley JM, Senior RM. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am J Pathol 2000;157:525-535.

  51. Kim KH, Burkhart K, Chen P, et al. Tissue inhibitor of metalloproteinase-1 deficiency amplifies acute lung injury in bleomycin-exposed mice. Am J Respir Cell Mol Biol 2005;33:271-279.

  52. Fattman CL, Chang LY, Termin TA, Petersen L, Enghild JJ, Oury TD. Enhanced bleomycin-induced pulmonary damage in mice lacking extracellular superoxide dismutase. Free Radic Biol Med 2003; 35:763-771.

  53. Bowler RP, Nicks M, Warnick K, Crapo JD. Role of extracellular superoxide dismutase in bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002;282:L719-L726.

  54. Pardo A, Ruiz V, Arreola JL, et al. Bleomycin-induced pulmonary fibrosis is attenuated in gamma-glutamyl transpeptidase-deficient mice. Am J Respir Crit Care Med 2003;167:925-932.

  55. Manoury B, Nenan S, Leclerc O, et al. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir Res 2005;6:11.




2020     |     www.medigraphic.com